The Impact of Commodification of Herbal Medicine by Pharmaceutical and Drug Development Companies

Nexus 15 (1):3 (2001)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,202

External links

  • This entry has no external links. Add one.
Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Private-sector research ethics: Marketing or good conflicts management? The 2005 John J. Conley lecture on medical ethics. [REVIEW]Rebecca Dresser - 2006 - Theoretical Medicine and Bioethics 27 (2):115-139.
Institutional mistrust in the organization of pharmaceutical clinical trials.Jill A. Fisher - 2008 - Medicine, Health Care and Philosophy 11 (4):403-413.
Exposing Nursing Students To the Marketing Methods of Pharmaceutical Companies.Murat Civaner, Ozlem Sarikaya, Sevim Ulupinar Alici & Gulcin Bozkurt - 2008 - Nursing Ethics 15 (3):396-410.
Antagonistic Synergy: Process and Paradox in the Development of New Agricultural Antimicrobial Regulations. [REVIEW]Wesley R. Dean & H. Morgan Scott - 2005 - Agriculture and Human Values 22 (4):479-489.
Ethical considerations in the use of direct-to-consumer advertising and pharmaceutical promotions: The impact on pharmaceutical sales and physicians. [REVIEW]R. Stephen Parker & Charles E. Pettijohn - 2003 - Journal of Business Ethics 48 (3):279-290.
Who's in the Business of Saving Lives?Pepe Lee Chang - 2006 - Journal of Medicine and Philosophy 31 (5):465-482.
Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
Vioxx and other pharmaceutical product withdrawals: ethical issues in ensuring the integrity of drug and medical device research, development and commercialization.K. L. Phua & F. I. Achike - 2007 - Clinical Ethics 2 (3):155-162.
Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines.Joo-Young Lee & Paul Hunt - 2012 - Journal of Law, Medicine and Ethics 40 (2):220-233.
Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem.Onyeka K. Osuji & Okechukwu Timothy Umahi - 2012 - Journal of Global Ethics 8 (2-3):139-167.
The Impact of Nanomedicine Development on North–South Equity and Equal Opportunities in Healthcare.Michael G. Tyshenko - 2009 - Studies in Ethics, Law, and Technology 3 (3).
Global health impact: A basis for labeling and licensing campaigns?Nicole Hassoun - 2012 - Developing World Bioethics 12 (3):121-134.
Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.

Analytics

Added to PP
2014-01-19

Downloads
2 (#1,755,150)

6 months
1 (#1,459,555)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references